Ectopic expression of L1196M and C1156Y leads to resistance to crizotinib in EML4-ALK-transformed Ba/F3 cells, indicating that these tumor-derived L1196M and C1156Y mutations decrease the tumor's sensitivity to ALK inhibitors [62]. Here, ALK is linked to neoplasm.